News

PharmExec1h
Roche’s Lunsumio-Polivy Combo Significantly Improves Outcomes in Relapsed or Refractory Large B-Cell Lymphoma
Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...
Opinion
PharmExec4hOpinion
Don’t Fall for the Call of Placebo-Controlled Vaccine Trials
In a functioning system, the kind of placebo-controlled vaccine trials that Secretary Kennedy is calling for would never get past an IRB, much less progress to an IND application. Vaccines are being ...
PharmExec21h
Roche’s Next-Gen Bispecific Antibody Shows Early Promise in Hemophilia A
Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...
PharmExec23h
FDA Grants Accelerated Approval to AstraZeneca, Daiichi Sankyo’s Datroway for Previously Treated, Locally Advanced or Metastatic EGFR-Mutated NSCLC
Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...